Rhesus macaques were immunized with purified virusderived simian immunodeficiency virus of macaques (SIV.~) 251/32H glycoprotein 130 (gpl30) or primed with recombinant vaccinia virus (VV) expressing the env gene of the SIV ..... BK28 clone and boosted subsequently with virus-derived gp130. High antibody titres of at least 10 ~ against recombinant gpl40 were induced with both vaccines. Analysis of the antibody specificity with a peptide ELISA revealed that different linear epitopes were recognized after administration of virus-derived gpl30 compared with those after priming with VV. Antibodies to some epitopes (peptides 10 and 49), which were also found in SIV-infected animals, were induced with both vaccines, whereas antibodies to other regions were induced by only one vaccine preparation. The analysis of the helper T cell response revealed a poor immunogenicity of the virus-derived gpl30, whereas priming with W induced a considerable helper T cell activity in all three vaccinees after the second VV infection. Using synthetic peptides, several epitopes were identified. Our observations show that immunization with a virus-derived gp 130 or live recombinant VV induces a considerably different antibody and helper T cell response. These differences in immunogenicity might have important implications for further vaccine development.
Introduction
The infection of rhesus macaques with simian immunodeficiency virus of macaques (SIVm~o) has proven to be a reliable model for the infection of humans with the human immunodeficiency virus (HIV) (for reviews see Schneider & Hunsmann, 1988; Desrosiers & Ringler, 1989; Letvin, 1990) . This model offers the opportunity to conduct vaccine studies, which may provide results important for human HIV vaccines. There have been numerous reports about successful vaccination of rhesus macaques with whole virus (Desrosiers et al., 1989; Murphey-Corb et al., 1989; Carlson et al., 1990; Stott et al., 1990; Cranage et al., 1992; Putkonen et aI., 1992; Hartung et al., 1992) or split virus vaccines (Desrosiers et al., 1989; Stahl-Hennig et al., 1992) . As cellular components contaminating whole virus vaccines may contribute to protection (Stott, 1991) , envelope glycoproteincontaining subunit vaccines have become more ira-portant. Indeed, vaccination with envelope glycoprotein as well as sequence-homologous peptides of HIV-2 or SIVm~ ~ protected macaques from infection or delayed virus spread and disease (Hu et al., 1992; Liike et al., 1993a; Shafferman et al., 1991) . However, most trials using recombinant SIV glycoprotein as a vaccine were not successful in protecting from challenge (Giavedoni et al., 1993; Mills et al., 1992) . It remains to be determined whether recombinant glycoprotein subunit vaccines have only limited success in protecting fi'om SIV infection because only a single viral protein was administered or because virus-derived glycoprotein is more immunogenic than recombinant antigens. The identification of B and T cell immunogenic determinants on the viral glycoprotein is a prerequisite to answer this question.
In this study we have compared the immunogenicity of virus-derived purified SIV .... gpl30 and a live recombinant SIV,~o gpl30-coding vaccinia virus (VV). The analysis of the antibody and the proliferative T cell response showed remarkable differences in the immune response against the two vaccines. Antibodies to some linear epitopes were induced by both vaccines, whereas other epitopes were immunogenic in only one of the two vaccine preparations. Interestingly, proliferative T cells 0001-1646 © 1993 SGM were induced only after vaccination with the recombinant VV. The specificity of the proliferating cells was different from animal to animal. The distinct immunogenicity of the two vaccines shows that the use of recombinant antigens is not necessarily comparable to the administration of virus-derived antigen preparations.
Methods
Animals, antigens and immunization scheme. The external glycoprotein gp 130 of SIV .... 251/32H was purified from whole virus grown in the human T cell line C8166. Pelleted virus was dissolved in buffer A (10 m~-Tris-HCl pH 8-0, 100 mM-KC1) and solubilized with 2% octylglycoside for 1 h at 4 °C. The suspension was diluted 10-fold with buffer B (buffer A containing 0.5 % octylglycoside) and centrifuged at 150000g for 2 h at 4 °C. The supernatant was adjusted to 1 mM each of CaCI~ and MnC12 and adsorbed to lentil lecti~Sepharose for 2 h. Thereafter, the lentil lectin-Sepharose was washed with a 10-fold volume of buffer B and the bound glycoproteins were eluted for 2 h with buffer C (buffer A containing 2% octylglycoside and 10% c~-methylmannopyranoside). The eluted glycoproteins were then centrifuged into a 20 to 70 % sucrose gradient at 200000 g at 4 °C overnight. Each gradient fraction was tested for the presence of gp 130 as described earlier (Lfike et al., 1993b) . The gpl30-containing fractions were pooled and stored at -80 °C.
For vaccine preparation the gp130 micelles exhibiting a purity of 80 to 85% (Ltike et al., 1993a, b) were mixed with keyhole limpet haemocyanin (KLH) at a ratio of 1 : 3. ELISA. ELISA plates with intermediate binding capacity (Greiner) were coated with 50 ng per well of recombinant SIVm~ o gp 140 (rgp 140; Repligen) in carbonate buffer (15 mM-Na2CO3, 35 mM-NaHCO3, 3 mMNaN 3, pH 9.6) for 1 h at room temperature and at 4 °C overnight. The coated plates were washed three times with PBS containing 0.05 % Tween-20 (PBS-Tween). Then 100 lal of serum dilution per well was incubated for 1 h at 37 °C. The plates were washed again three times with PBS-Tween and incubated for 1 h with 100 lal of horseradish peroxidase-conjugated goat anti-human antiserum (Medac) diluted 1:1000. After three washes, the bound antibodies were detected by adding 40 lag o-phenylenediamine and 0.05 % H202 in 100 lal citrate buffer (0.1 M, pH 5). The A492 values were determined with an ELISA reader. The ELISA titres are expressed as the reciprocal serum dilutions yielding A492 values twofold above those of the respective dilutions of the preimmune sera. Monkey sera were examined for peptide-specific antibodies using a peptide ELISA. The peptides were 20-mers overlapping with 10 amino acids each spanning the whole SIV .... 251/32H gpl30. Three peptides (amino acids 61 to 80, 391 to 410, 471 to 490) were not available and therefore not tested. The peptides were kindly provided by the programme EVA of the European Community. Peptides were coated at 0.25 ~tg in 100 lal H20 per well onto high-binding 96-well ELISA plates (Greiner) at room temperature for 1 h and at 60 °C overnight. The plates were washed three times with PBS Tween and the sera were applied at a 1:100 dilution. The plates were further processed as described above. A492 values twofold above the background obtained with unrelated peptides were considered positive.
T eellproliferation assay. Peripheral blood mononuclear cells (PBMCs)
from the rhesus macaques were isolated from whole citrated blood by Ficoll-diatrizoate density gradient centrifugation. Cells (1 x 105) were seeded in 100 lal cell growth (CG) medium (Camon; Trees & Schreier, 1980) supplemented with 1% human AB serum in U-bottomed 96-well plates. Cells were stimulated with 0.5 lag per well of rgpl40. After 3 days at 37 °C in a humidified CO 2 atmosphere, the wells were refed with 100 lal medium per well and incubated for a further 4 days. During the last 6 h 0.5 laCi [3H]thymidine was added per well. The cells were harvested onto glass fibre filters and the incorporated radioactivity was determined in a r-counter. The stimulation index (SI) was calculated by dividing the mean counts of triplicate wells by the mean counts of cultures without antigen. SI values over 2~0 were considered positive.
To determine the proliferative activity of T cell subsets, PBMCs were separated with CD4-specific immunomagnetic beads as described and the remaining cells, simultaneously with the cells bound to the beads, were cultured as described above. The major histocompatibility complex (MHC) restriction of the antigen presentation for the proliferating cells was assessed by adding 50 nl of ascitic fluid containing the monoclonal antibodies (MAbs) W6/32 (anti-MHC class I) (Dakopatts) or Q513 (anti-MHC class II) (BioGenex).
Helper T cell epitopes were determined by restimulating 5 x 104 PBMCs per well with 1 lag of SIV ..... gpl30 peptides. Cultures with a control peptide from the SIVm~ o Gag protein (NANPDCKLVLKGLGVNPTLE) and without peptide served as controls.
Results

High SIVmac gpl30-specific antibody titres are induced after vaccination
The vaccinated animals generated high anti-gpl40 antibody titres during the immunization period (Fig. 1 ). Titres were lower in animals immunized with virusderived gpl30 (Fig. 1 a) than in those primed with live wild-type or recombinant VV expressing the gp 130 and boosted with virus-derived gpl30 (Fig. l b) . Antibody titres 2 weeks after the last immunization ranged from 104 to l0 s in the animals immunized with virus-derived gpl30 having dropped from 107 despite further boosting in animal 1715. Two of the animals primed with recombinant VV before boosting had developed titres of 106, whereas one animal primed with recombinant VV and the two animals primed with wild-type VV showed titres of 103 to 104.
Immunization with the two vaccines induces antibodies to different linear epitopes
The specificity of the gpl30-specific antibodies induced by immunization with either purified virus-derived gp 130 or recombinant gpl30-coding VV was assessed with a peptide ELISA using sera after the last booster from animals immunized with the virus-derived gpl30 and sera obtained 2 weeks after the VV reinfection from recombinant VV-immunized animals. The reactivity patterns were compared to those of sera obtained from SIV .... 251/32H-infected animals (Fig. 2) . Peptide 10 was detected by antisera from all nine SIV-infected macaques as well as from the six vaccinees. A comparable ubiquitous reactivity was detected against peptide 49. A reactivity against a Sigma e neutralizing domain (amino acids 171 to 189) was observed in three infected and five vaccinated macaques, which generated antibodies to peptide 16, whereas the naturally occurring reactivity to peptide 15 was induced only in recombinant VVimmunized macaques. A reactivity to peptides 30 and 31 homologous to HIV-1 V3 was seen in the infected and virus-derived gpl30-immunized animals. Antibodies to peptides 2, 3 and 34 were detected in recombinant VVimmunized, but not in the SIV .... -infected animals. After three boosters with virus-derived gp130 the recombinant VV-immunized animals had acquired a reactivity against peptide 31, whereas antibodies to peptides 3, 20 and 34 were no longer detectable (data not shown).
Immunization with recombinant VV, and not with viruspurified gp l30, induces antigen-specific proliferative T cells
The induction of a helper T cell response in the animals immunized with the different vaccines was determined using a T cell proliferation assay. After five immuniz- ations, none of the three animals that had received purified virus-derived gp 130 displayed a sustained T cell response to rgpl40. Only PBMCs from animal 1715 exhibited a transient proliferative activity after the first booster immunization (Fig. 3a) . In contrast, two (1729 and 1768) of the three animals that had been infected with the rgpl40-specific recombinant VV showed proliferative T cells as early as 4 weeks after the initial immunization. This T cell response was strongly increased after the second VV infection and was maintained after the boosters with virus-derived gpl30 (Fig. 3b) . The third recombinant VV-immunized animal (1769) generated rgpl40-specific proliferative T cells after the W reinfection (Fig. 3b) . One of the animals primed with gpl40-specific wild-type VV showed an antigen-specific proliferation at 18 weeks post-infection (p.i.), whereas the other animal and the two KLH-immunized controls did not exhibit proliferative rgp140-specific T cells at any time (data not shown).
To characterize the proliferating cells from the recombinant VV-immunized macaques, CD4 + cells were isolated from whole PBMCs and examined for antigenspecific proliferation simultaneously with cells remaining after depletion and unseparated PBMCs. The proliferative activity in response to rgpl40 exhibited by the unfractionated PBMCs was also present in the purified CD4 + cells. In contrast, the CD4+-depleted cells were not stimulated by rgpl40. Thus, the SIV rgpl40-specific proliferation was attributed to CD4 + cells.
To prove an MHC-mediated antigen presentation, MAbs to MHC class I or class II DR were added to the cultures. The proliferative response in cultures without MAb was maintained in cultures containing MAb specific for MHC class I. Cells in cultures treated with MAb against MHC class II did not proliferate. There- fore, the antigen stimulus required for proliferation was associated with MHC class II DR molecules.
The proliferating cells are directed against several epitopes on SIV gpl30
The specificity of the proliferating cells was further determined by adding SIVm~ o gpl30 sequence-homologous peptides to PBMC cultures. None of the three animals immunized with recombinant VV showed a proliferative response to the control peptide derived from SIVm~o Gag. However, each of the animals possessed proliferative cells specific for some peptides of SIVm~ o gp 130. Three regions of gp 130 were immunogenic in two of the three animals (peptides 2, 19 and 34) and several additional peptides induced a proliferative T cell response in only one of the animals.
Discussion
Rhesus macaques were immunized repeatedly with purified virus-derived SIV .... gpl30 or primed with recombinant VV encoding the SIVma e env gene and boosted subsequently with virus-derived gpl30 to compare the immunogenicity of the two vaccines. Glycoprotein-specific antibodies were induced by both vaccines and multiple linear epitopes were recognized, indicating a broad immunogenicity of the SIVma e gpl30. However, the analysis of the immunogenic epitopes revealed remarkable differences. Although it has to be taken into account that the animal numbers were relatively small, the observed differences are validated by the analysis of the sera of recombinant VV-primed animals after boosting with virus-derived gpl30. After the last booster the animals' reactivity patterns had changed and resembled those of animals receiving only virus-derived gp 130. Antibodies to some epitopes were induced by both vaccine preparations, whereas antibodies to other gpl30 regions were generated only by one of the vaccines. The comparison to sera of SIV-infected animals showed that peptides 10 and 49 were ubiquitously recognized among all animals. Interestingly, sequence comparison of the BK28 SIV .... clone used for the construction of the recombinant VV and the 32H isolate yielding the virusderived gpl30 preparation revealed three amino acid changes in peptide 10 and none in peptide 49. Overall, there was no correlation between the different immunogenicity of the two vaccines and sequence variation of the epitopes. The region homologous to HIV-1 V3 (SIV peptides 30 and 31) was detected by sera from experimentally infected macaques as well as from sera of virus-derived gpl30-immunized animals, whereas only one of the recombinant VV-immunized animals had generated antibodies to this region. Since the V3 region of the genetically divergent SIVag m (SIV of African green monkeys) is highly immunogenic in infected animals (Siegel et al., 1992) , the low immunogenicity of the V3 region of the recombinant VV gpl30 is surprising. According to recent reports, the V3 analogous region of SIVm~o does not contain neutralizing epitopes. Instead, in addition to a conformation-dependent epitope (Kent et al., 1992) , a neutralizing epitope was located in the V2 equivalent region comprising amino acid positions 171 to 189 (Kent et at., 1992; Benichou et al., 1992) corresponding to peptides 15 and 16. Interestingly, only the animal receiving the recombinant VV with two amino acid changes in peptide 15 exhibited a reactivity against both peptides, whereas the macaques immunized with sequence-homologous virus-derived gpl30 reacted only In conclusion, the administration of a virus-derived and a recombinant SIVm, , gpl30 vaccine has revealed that the antibody recognition patterns vary considerably. Furthermore, the live vaccine vector induced a helper T cell response much more efficiently than the protein vaccine in this experimental setting. Although the relevance for vaccine protection has to be evaluated, these results may have important implications for further vaccine development against SIV and HIV.
